Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma
<i>KRAS</i>-wt PDAC diagnosed at a younger age more frequently harbors actionable mutations, highlighting the importance of comprehensive genomic profiling to guide targeted therapeutic interventions in this patient population.
Authors
- Simona Casalino (ORCID: https://orcid.org/0000-0002-0895-6387)
- A. Sordo
- Enza Scarlato (ORCID: https://orcid.org/0009-0009-3263-9830)
- E. San Lorenzo (ORCID: https://orcid.org/0000-0002-8189-7213)
- Valerio De Vita (ORCID: https://orcid.org/0000-0002-1483-8440)
- Davide Melisi (ORCID: https://orcid.org/0000-0002-4031-7585)
- Alberto Quinzii (ORCID: https://orcid.org/0000-0002-2142-1352)
- Camilla Zecchetto (ORCID: https://orcid.org/0000-0002-1028-6431)
- L. Mendo
- Giovanni Butturini (ORCID: https://orcid.org/0000-0002-9172-4885)
Institutions
- University of Verona (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Casa di Cura Villa Garda (IT)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100179
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Celgene
- Incyte
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Università degli Studi di Verona
- Servier
- Ministero dell'Università e della Ricerca